Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on ITCI. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Hold” and an average target price of $109.70.

Intra-Cellular Therapies Stock Performance

Intra-Cellular Therapies stock opened at $131.87 on Tuesday. The firm has a 50 day moving average of $131.42 and a 200 day moving average of $109.62. The firm has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies has a 12-month low of $64.09 and a 12-month high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. On average, analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Hedge Funds Weigh In On Intra-Cellular Therapies

Hedge funds have recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB grew its holdings in Intra-Cellular Therapies by 124.3% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 133 shares during the last quarter. Accredited Wealth Management LLC bought a new position in Intra-Cellular Therapies during the 4th quarter valued at about $28,000. GAMMA Investing LLC grew its holdings in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Intra-Cellular Therapies by 452.5% during the 1st quarter. Farther Finance Advisors LLC now owns 884 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 724 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new position in Intra-Cellular Therapies during the 4th quarter valued at about $96,000. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.